-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Critical Comparison: MaxCyte (NASDAQ:MXCT) and Data Knights Acquisition (NASDAQ:DKDCA)
Critical Comparison: MaxCyte (NASDAQ:MXCT) and Data Knights Acquisition (NASDAQ:DKDCA)
Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) and MaxCyte (NASDAQ:MXCT – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.
Valuation & Earnings
This table compares Data Knights Acquisition and MaxCyte's gross revenue, earnings per share (EPS) and valuation.
Get Data Knights Acquisition alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Data Knights Acquisition | N/A | N/A | $5.14 million | N/A | N/A |
MaxCyte | $33.89 million | 15.44 | -$19.08 million | ($0.23) | -22.26 |
Data Knights Acquisition has higher earnings, but lower revenue than MaxCyte.
Analyst Ratings
This is a summary of current ratings and recommmendations for Data Knights Acquisition and MaxCyte, as reported by MarketBeat.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Data Knights Acquisition | 0 | 0 | 0 | 0 | N/A |
MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
MaxCyte has a consensus price target of $9.00, indicating a potential upside of 75.78%. Given MaxCyte's higher possible upside, analysts clearly believe MaxCyte is more favorable than Data Knights Acquisition.
Profitability
This table compares Data Knights Acquisition and MaxCyte's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Data Knights Acquisition | N/A | N/A | N/A |
MaxCyte | -56.29% | -9.12% | -8.21% |
Insider & Institutional Ownership
78.5% of Data Knights Acquisition shares are owned by institutional investors. Comparatively, 66.7% of MaxCyte shares are owned by institutional investors. 23.1% of Data Knights Acquisition shares are owned by insiders. Comparatively, 5.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Data Knights Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.
Summary
Data Knights Acquisition beats MaxCyte on 6 of the 10 factors compared between the two stocks.
About Data Knights Acquisition
(Get Rating)
Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
About MaxCyte
(Get Rating)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Data Knights Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Data Knights Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) and MaxCyte (NASDAQ:MXCT – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.
数据骑士收购(纳斯达克:DKDCA-GET评级)和MaxCyte(纳斯达克:MXCT-GET评级)都是小盘医疗公司,但哪一家是优势业务?我们将根据这两家公司的机构所有权、收益、风险、盈利能力、股息、估值和分析师的建议对它们进行对比。
Valuation & Earnings
估值与收益
This table compares Data Knights Acquisition and MaxCyte's gross revenue, earnings per share (EPS) and valuation.
下表比较了数据骑士收购和MaxCyte的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Data Knights Acquisition | N/A | N/A | $5.14 million | N/A | N/A |
MaxCyte | $33.89 million | 15.44 | -$19.08 million | ($0.23) | -22.26 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
数据骑士收购 | 不适用 | 不适用 | 514万美元 | 不适用 | 不适用 |
Maxcell | 3389万美元 | 15.44 | -1908万美元 | ($0.23) | -22.26 |
Data Knights Acquisition has higher earnings, but lower revenue than MaxCyte.
数据骑士收购的收益高于MaxCyte,但营收低于MaxCyte。
Analyst Ratings
分析师评级
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Data Knights Acquisition | 0 | 0 | 0 | 0 | N/A |
MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
数据骑士收购 | 0 | 0 | 0 | 0 | 不适用 |
Maxcell | 0 | 0 | 1 | 0 | 3.00 |
MaxCyte has a consensus price target of $9.00, indicating a potential upside of 75.78%. Given MaxCyte's higher possible upside, analysts clearly believe MaxCyte is more favorable than Data Knights Acquisition.
Maxcell的一致目标价为9.00美元,表明潜在上行空间为75.78%。考虑到MaxCyte更有可能的上行空间,分析师们显然认为MaxCyte比Data Knight的收购更有利。
Profitability
盈利能力
This table compares Data Knights Acquisition and MaxCyte's net margins, return on equity and return on assets.
此表比较了Data Knight收购和MaxCyte的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Data Knights Acquisition | N/A | N/A | N/A |
MaxCyte | -56.29% | -9.12% | -8.21% |
净利润率 | 股本回报率 | 资产回报率 | |
数据骑士收购 | 不适用 | 不适用 | 不适用 |
Maxcell | -56.29% | -9.12% | -8.21% |
Insider & Institutional Ownership
内部人与机构所有权
78.5% of Data Knights Acquisition shares are owned by institutional investors. Comparatively, 66.7% of MaxCyte shares are owned by institutional investors. 23.1% of Data Knights Acquisition shares are owned by insiders. Comparatively, 5.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
78.5%的数据骑士收购股份由机构投资者持有。相比之下,MaxCyte 66.7%的股份由机构投资者持有。数据骑士收购的23.1%股份由内部人士持有。相比之下,MaxCyte 5.1%的股份由内部人士持有。强大的机构持股表明,捐赠基金、大型基金管理公司和对冲基金相信,一家公司的长期表现将好于大盘。
Volatility and Risk
波动性和风险
Data Knights Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.
数据骑士收购的贝塔指数为0.01,表明其股价的波动性比标准普尔500指数低99%。相比之下,MaxCyte的贝塔系数为0.44,这表明其股价的波动性比标准普尔500指数低56%。
Summary
摘要
Data Knights Acquisition beats MaxCyte on 6 of the 10 factors compared between the two stocks.
数据骑士收购在两只股票之间的10个因素中有6个超过了MaxCyte。
About Data Knights Acquisition
关于数据骑士的收购
(Get Rating)
(获取评级)
Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
数据骑士收购公司没有重要的业务。它打算与数据中心和互联网技术领域的一家或多家企业进行合并、资本股票交换、资产收购、股票购买、重组或类似的业务合并。该公司成立于2021年,总部设在英国切辛顿。
About MaxCyte
关于MaxCyte
(Get Rating)
(获取评级)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Maxcell,Inc.是一家全球生命科学公司,致力于下一代细胞疗法的发现、开发和商业化。其产品包括:Expert ATx,一种用于中小规模转基因的静态电穿孔仪器;Expert STx,一种用于蛋白质生产和药物开发的流动电穿孔设备,以及用于基于细胞分析的治疗靶点的表达;Expert GTx,一种用于治疗应用中大规模转基因的流动电穿孔设备;以及Expert VLx,用于超大规模细胞工程。该公司还提供用于处理和电穿孔电池的一次性处理组件(PAS);以及支持PAS的配件,如电穿孔缓冲液和软件协议。该公司成立于1998年,总部设在马里兰州的罗克维尔。
Receive News & Ratings for Data Knights Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Data Knights Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收数据骑士收购的新闻和评级-在下面输入您的电子邮件地址,以通过MarketBeat.com的免费每日电子邮件时事通讯接收对Data Knight收购和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧